文献速递免疫规划传染病防控与疫情报告

孟加拉国幼儿三价流感疫苗预防实验室确诊流感的随机试验疗效

Efficacy of trivalent influenza vaccine against laboratory-confirmed influenza among young children in a randomized trial in Bangladesh.
PubMed 文献 · Vaccine · 2017-10-31

在孟加拉国达卡开展平行双盲随机对照试验,6-23月龄儿童按1:1接种三价灭活流感疫苗(IIV3)或灭活脊灰疫苗(IPV),随访一年。IIV3组流感发病率为10例/100儿童年,IPV组为15例/100儿童年,对任何RT-PCR确诊流感的疫苗效力为31%(95%CI 18-42%)。

要点

  • 6-23月龄儿童接种IIV3后,RT-PCR确诊流感发病率低于IPV组。
  • 总体疫苗效力为31%(95%CI 18-42%),对任何RT-PCR确诊流感。
  • 疫苗效力随季节变化,但按流感型/亚型、年龄和性别相似。

核心结论

  • 幼儿接种IIV3可显著减少实验室确诊流感,但需探索佐剂疫苗或标准成人剂量等额外策略以寻找更有效疫苗。

研究设计与样本

  • 平行、双盲、随机对照试验,2010年8月至2014年3月在孟加拉国达卡开展。
  • 6-23月龄儿童按1:1随机接种IIV3或IPV,间隔一个月接种两剂儿童剂量,随访一年。
  • 分析纳入所有接受第一剂疫苗的儿童,比较试验组间RT-PCR确诊流感的年发病率。

主要发现

  • 四轮接种共入组随机4081名儿童,IIV3组贡献2576儿童年观察,IPV组贡献2593儿童年。
  • IIV3组流感发病率为10例/100儿童年,IPV组为15例/100儿童年。
  • 总体疫苗效力为31%(95%CI 18-42%),针对任何RT-PCR确诊流感。
  • 疫苗效力随季节变化,但按流感型/亚型、参与者年龄和性别相似。

关键数值与推荐

  • 疫苗效力估计为1-(疾病率比)×100%,使用未调整泊松回归。
  • 试验注册号ClinicalTrials.gov NCT01319955。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论提出需探索佐剂疫苗或标准成人疫苗剂量等额外流感疫苗策略,以寻找对低收入国家幼儿更有效的流感疫苗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Few trials have evaluated influenza vaccine efficacy (VE) in young children, a group particularly vulnerable to influenza complications. We aimed to estimate VE against influenza in children aged <2 years in Bangladesh; a subtropical setting, where influenza circulation can be irregular. METHODS: Children aged 6-23 months were enrolled 1:1 in a parallel, double-blind, randomized controlled trial of trivalent inactivated influenza vaccine (IIV3) versus inactivated polio vaccine (IPV); conducted August 2010-March 2014 in Dhaka, Bangladesh. Children received two pediatric doses of vaccine, one month apart, and were followed for one year for febrile and respiratory illness. Field assistants conducted weekly home-based, active surveillance and ill children were referred to the study clinic for clinical evaluation and nasopharyngeal wash specimen collection. Analysis included all children who received a first vaccine dose and compared yearly incidence of reverse transcription polymerase chain reaction (RT-PCR)-confirmed influenza between trial arms. The VE was estimated as 1-(rate ratio of illness) × 100%, using unadjusted Poisson regression. The trial was registered with ClinicalTrials.gov, number NCT01319955. RESULTS: Across four vaccination rounds, 4081 children were enrolled and randomized, contributing 2576 child-years of observation to the IIV3 arm and 2593 child-years to the IPV arm. Influenza incidence was 10 episodes/100 child-years in the IIV3 arm and 15 episodes/100 child-years in the IPV arm. Overall, the VE was 31% (95% confidence interval 18, 42%) against any RT-PCR-confirmed influenza. The VE varied by season, but was similar by influenza type/subtype and participant age and sex. CONCLUSIONS: Vaccination of young children with IIV3 provided a significant reduction in laboratory-confirmed influenza; however, exploration of additional influenza vaccine strategies, such as adjuvanted vaccines or standard adult vaccine doses, is warranted to find more effective influenza vaccines for young children in low-income countries.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Rolfes MA, Goswami D, Sharmeen AT, et al. Efficacy of trivalent influenza vaccine against laboratory-confirmed influenza among young children in a randomized trial in Bangladesh. Vaccine. 2017. PMID: 29100706. doi:10.1016/j.vaccine.2017.10.074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。